Autolus Therapeutics Receives Prix Galien UK Award
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) announced it received the 2026 Prix Galien UK Award for Best Biotechnology Product. The award is presented by the Galien Foundation and selected by a 12-member UK Awards Committee of healthcare experts.
According to Autolus, the recognition reflects its mission to translate pioneering scientific research, developed with University College London, into new treatment options for patients, and highlights the dedication of its teams and their commitment to patients.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Investor conferences | Neutral | +0.0% | Participation in two early‑June investor conferences with webcast access. |
| May 21 | Clinical data update | Positive | +3.0% | ASCO 2026 post‑hoc FELIX study analysis showing favorable benefit–risk profile. |
| May 14 | Q1 2026 earnings | Positive | -7.0% | Strong AUCATZYL revenue growth but ongoing net loss and restructuring plan. |
| May 05 | Earnings call notice | Neutral | +4.5% | Announcement of timing and access details for Q1 2026 results call. |
| Apr 29 | Cost reduction plan | Positive | +0.0% | Operational efficiency initiative with workforce reduction and revenue guidance reiteration. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed follow-through: positive clinical and corporate updates sometimes align with upside, but earnings and efficiency actions have seen flat or negative reactions.
Over the last few months, Autolus issued several updates, including cost‑reduction and efficiency measures on Apr 29, an earnings call notice on May 5, Q1 2026 results on May 14, and clinical data for obe‑cel at ASCO on May 21. Price reactions ranged from -7.02% to +4.46% or flat. Against this backdrop, the Prix Galien UK award fits into a narrative of growing external validation alongside ongoing commercialization and restructuring.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare.
“We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with University College London, to translate pioneering scientific research into new treatment options for patients in need. As a clinician, it is tremendously rewarding to see this vision become a reality. This award reflects the dedication of our teams, whose work is driven every day by a shared commitment to patients,” said Dr. Martin Pule, Founder and Chief Scientific Officer of Autolus, Clinical Senior Lecturer in the Department of Haematology at the UCL Cancer Institute, and Honorary Consultant in Haematology at University College London Hospital.
About The Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives. Established in Paris in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
Executive Director, Investor Relations & External Communications
+1 617-967-0207
a.cray@autolus.com
